 |
Synthetic glucagon analogue modified to contain 7 amino acid substitutions |
|---|---|
| Trade Name | |
| Orphan Indication | Congenital hyperinsulinism |
| EU Market Approval | EU |
| EU Designation Date | 2017-06-20 00:00:00 |
| Sponsor | Zealand Pharma A/S |
| |
Synthetic glucagon analogue modified to contain 7 amino acid substitutions |
|---|---|
| Trade Name | |
| Orphan Indication | Congenital hyperinsulinism |
| EU Market Approval | EU |
| EU Designation Date | 2017-06-20 00:00:00 |
| Sponsor | Zealand Pharma A/S |